• 1
    Westphal C. Eigentümliche mit Einschlafen verbundene Anfälle. Arch Psychiatr Nervenkr 1877; 7: 631635.
  • 2
    Gelineau J. De la narcolepsie. Gaz des Hôp (Paris) 1880; 55: 635637.
  • 3
    American Academy of Sleep Medicine. ICSD-2-International Classification of Sleep Disorders, 2nd edn. Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine, 2005.
  • 4
    Standards of Practice Committee of the American Sleep Disorders Association. Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep 1994; 17: 348351.
  • 5
    Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001; 24: 451466.
  • 6
    Britton T, Hansen A, Hicks J, et al. Guidelines on the Diagnosis and Management of Narcolepsy in Adults and Children. Evidence-Based Guidelines for the UK with Graded Recommendations. Ashtead, UK: Taylor Patten Communications Ltd, 2002.
  • 7
    Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. European Journal of Neurology 2004; 11: 577581.
  • 8
    Lin JS, Roussel B, Akaoka H, Fort P, De Billy G, Jouvet M. Role of catecholamines in modafinil and amphetamine induced wakefulness, a comparative pharmacological study. Brain Research 1992; 591: 319326.
  • 9
    Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17: 436437.
  • 10
    Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. European Journal of Pharmacology 1996; 306: 3339.
  • 11
    Dauvilliers Y, Neidhart E, Lecendreux M, Billiard M, Tafti M. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Molecular Psychiatry 2001; 6: 367372.
  • 12
    Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. Journal of Neuroscience 2001; 21: 17871794.
  • 13
    Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicenter study. Sleep 1994; 17 (Suppl.): 107112.
  • 14
    Broughton RJ, Fleming JAE, George CFP, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49: 444451.
  • 15
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Annals of Neurology 1998; 43: 8897.
  • 16
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54: 11661175.
  • 17
    Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22: 757765.
  • 18
    Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Medicine 2000; 1: 109116.
  • 19
    Mitler MM, Hirsh J, Hirshkowitz M, Guilleminault C, for the US Modafinil in Narcolepsy Multicenter Study Group. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Medicine 2000; 1: 231243.
  • 20
    Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen of modafinil for improving daytime wakefulness in patients with narcolepsy. Clinical Neuropharmacology 2003; 26: 252257.
  • 21
    Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam l-hydroxylation. British Journal of Clinical Pharmacology 2000; 50: 333337.
  • 22
    Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 1985; 290: 11671170.
  • 23
    Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. Journal of Clinical Neurophysiology 1990; 7: 93118.
  • 24
    Mitler MM, Hajdukovic R, Erman M. Treatment of narcolepsy with methamphetamine. Sleep 1993; 16: 306317.
  • 25
    Chen SY, Cloift SJ, Dahlitz MJ, Dunn G, Parkes JD. Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. Journal of Sleep Research 1995; 4: 113118.
  • 26
    Mitler MM, Aldrich MS, Koob GF, Zarcone V. Narcolepsy and its treatment with stimulants (ASDA standards of practice). Sleep 1994; 17: 352371.
  • 27
    Guilleminault C. Amphetamines and narcolepsy: use of the Stanford database. Sleep 1993; 16: 199201.
  • 28
    Parkes JD, Dahlitz M. Amphetamine prescription. Sleep 1993; 16: 201203.
  • 29
    Mitler MM, Shafor R, Hajdukovik R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9: 260264.
  • 30
    Yoss RE, Daly D. Treatment of narcolepsy with Ritalin. Neurology 1959; 9: 171173.
  • 31
    Honda Y, Hishikawa Y, Takahashi Y. Long-term treatment of narcolepsy with methylphenidate (Ritalin®). Current Therapeutic Research 1979; 25: 288298.
  • 32
    Guilleminault C, Carskadon MA, Dement WC. On the treatment of rapid eye movement narcolepsy. Archives of Neurology 1974; 30: 9093.
  • 33
    Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gammahydroxybutyrate. Canadian Journal of Neurological Sciences 1979; 6: 16.
  • 34
    Scrima L, Hartman PG, Johnson FH, Jr, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biological Psychology 1989; 26: 331343.
  • 35
    Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993; 16: 216220.
  • 36
    US Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 4249.
  • 37
    US Xyrem Multicenter Study Group. A 12-month, open-label multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26: 3135.
  • 38
    Mamelak M, Black J, Montplasir J. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27: 13271334.
  • 39
    The Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. Journal of Clinical Sleep Medicine 2005; 1: 391397.
  • 40
    Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29: 939946.
  • 41
    Honda Y, Hishikawa Y. A long-term treatment of narcolepsy and excessive daytime sleepiness with pemoline (Bentanamin®). Current Therapeutic Research 1980; 27: 429441.
  • 42
    Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986; 9: 265268.
  • 43
    Parkes JD, Schachter M. Mazindol in the treatment of narcolepsy. Acta Neurologica Scandinavica 1979; 60: 250254.
  • 44
    Vespignani H, Barroche G, Escaillas JP, Weber M. Importance of mazindol in the treatment of narcolepsy. Sleep 1984; 7: 274275.
  • 45
    Alvarez B, Dahlitz M, Grimshaw J, Parkes JD. Mazindol in long-term treatment of narcolepsy. Lancet 1991; 337: 12931294.
  • 46
    Wyatt R, Fram D, Buchbinder R, Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. New England Journal of Medicine 1971; 285: 987999.
  • 47
    Hublin C, Partinen M, Heinonen E, Puuka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 20952101.
  • 48
    Mayer G, Meier-Ewert K. Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clinical Neuropharmacology 1995; 18: 306319.
  • 49
    Reinish LW, MacFarlane JG, Sandor P, Shapiro CM. REM changes in narcolepsy with selegiline. Sleep 1995; 18: 362367.
  • 50
    Rogers AE, Aldrich MS. The effect of regularly scheduled naps on sleep attacks and excessive daytime sleepiness associated with narcolepsy. Nursing Research 1993; 42: 111117.
  • 51
    Rogers AE, Aldrich MS, Lin X. Comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001; 24: 385391.
  • 52
    Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993; 16: 444456.
  • 53
    US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Medicine 2004; 5: 119123.
  • 54
    Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Medicine 2005; 6: 415421.
  • 55
    Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Diseases of the Nervous System 1960; 21: 13.
  • 56
    Hishikawa Y, Ida H, Nakai K, Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). Journal of the Neurological Sciences 1965; 3: 453461.
  • 57
    Passouant P, Baldy-Moulinier M. Données actuelles sur le traitement de la narcolepsie. Action des imipraminiques. Concours Médical 1970; 92: 19671970.
  • 58
    Schmidt HS, Clark RW, Hyman PR. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. American Journal of Psychiatry 1977; 134: 183185.
  • 59
    Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. Journal of Neurology, Neurosurgery and Psychiatry 1980; 43: 171174.
  • 60
    Shapiro CM. Treatment of cataplexy with clomipramine. Archives of Neurology 1975; 32: 653656.
  • 61
    Guilleminault C, Raynal D, Takahashi S, Carkadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurologica Scandinavica 1976; 54: 7187.
  • 62
    Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Progress in Neurobiology 1997; 52: 2778.
  • 63
    Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurologica Scandinavica 1986; 74: 297303.
  • 64
    Langdon N, Bandak S, Shindler J, Parkes JD. Fluoxetine in the treatment of cataplexy. Sleep 1986; 9: 371372.
  • 65
    Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994; 44: 707709.
  • 66
    Thirumalai SS, Shubin RA. The use of citalopram in resistant cataplexy. Sleep Medicine 2000; 1: 313316.
  • 67
    Poryazova R, Siccoli M, Werth E, Bassetti C. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005; 65: 967968.
  • 68
    Guilleminault C, Mancuso J, Quera Salva MA, et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 1986; 9: 275279.
  • 69
    Larrosa O, De La Liave Y, Barrio S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy. Sleep 2001; 24: 282285.
  • 70
    Smith M, Parkes JD, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. Journal of Sleep Research 1996; 5 (Suppl. 1): 217.
  • 71
    Thorpy MJ, Snyder M, Aloe FS, Ledereich PS, Starz KE. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 1992; 15: 212216.
  • 72
    Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986; 9: 285289.
  • 73
    Schuld A, Kraus T, Haack M, Hinze-Selch D, Pollmächer T. Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder. Journal of Sleep Research 1999; 8: 321322.
  • 74
    Yeh SB, Schenck CH. A case of marital discord and secondary depression with attempted suicide resulting from REM sleep behavior disorder in a 35-year-old woman. Sleep Medicine 2004; 5: 151154.
  • 75
    Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Medicine 2003; 4: 281284.
  • 76
    Baker TL, Guilleminault C, Nino-Murcia G, Dement WC. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986; 9: 232242.
  • 77
    Mayer G, Kesper K, Peter H, Ploch T, Leinweber T, Peter JH. Comorbidity in narcoleptic patients. Deutsche Med Wochenschr 2002; 127: 19421946.
  • 78
    Montplaisir J, Michaud M, Denesle R, Gosselin A. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Medicine 2000; 1: 163167.
  • 79
    Boivin DB, Montplaisir J, Poirier G. The effects of L-Dopa on periodic leg movements and sleep organization in narcolepsy. Clinical Neuropharmacology 1989; 16: 339345.
  • 80
    Bedard MA, Montplaisir J, Godbout R, Lapierre O. Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clinical Neuropharmacology 1989; 12: 2936.
  • 81
    Boivin DB, Lorrain D, Montplaisir J. Effects of bromocriptine on periodic limb movements in human narcolepsy. Neurology 1993; 43: 21342136.
  • 82
    Roth B, Nevsimalova S. Depression in narcolepsy and hypersomnia. Schweizer Archiv für Neurologie und Psychiatrie 1975; 116: 291300.
  • 83
    Kales A, Soldatos CR, Bixler EO, et al. Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology. Archives of Neurology 1982; 39: 169171.
  • 84
    Vourdas A, Shneerson JM, Gregory CA, et al. Narcolepsy and psychopathology; is there an association? Sleep Medicine 2002; 3: 353360.
  • 85
    Shiba T, Fujiki N, Wisor JP, Dale EM, Sakurai T, Nishino S. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004; 27 (Abstract Suppl.): A241
  • 86
    Fujiki N, Yoshida Y, Ripley B., Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 orexin A in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003; 26: 953959.
  • 87
    Murillo-Rodriguez E, Arias-Carrion O, Xu M, Blanco-Centurion C, Drucker-Colin R, Shiromani PJ. Time course of survival of hypocretin neuronal transplantation into the pons of adult rats. Sleep 2004; 27 (Abtract Suppl.): A238.
  • 88
    Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. Journal of Sleep Research 2003; 12: 347348.
  • 89
    Dauvilliers Y, Carlander B, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Annals of Neurology 2004; 56: 905908.
  • 90
    Zuberi SM, Mignot E, Ling L, Mcarthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. Journal of Sleep Research 2004; 13 (Suppl. 1): 828.